Latest news with #Tarrytown
Yahoo
15-07-2025
- Health
- Yahoo
Dolores Catania Teams Up with Advanced Herbals®, from the Makers of Dramamine®, to Launch The Dish on GLP-1s Content Series and Tackle One of the Most Common Complaints from GLP-1 Users: Nausea
Advanced Herbals® and the reality TV star are sharing new, original content aimed to help the majority (64%) of GLP-1 users who wish they had more education about the medications' side effects TARRYTOWN, N.Y., July 15, 2025 /PRNewswire/ -- Side effects can crash the GLP-1 party – and most people aren't prepared for it. A survey commissioned by Advanced Herbals®, from the makers of Dramamine®, and Fleet® revealed that nausea and constipation are among the most common side effects reported by GLP-1 users, affecting 42% and 29% respectively – often without warning. Nearly two-thirds (64%) of GLP-1 users surveyed wished they had received more education about side effects prior to starting treatment, and 61% of users agreed the symptoms were more real than they had anticipated, indicating a potential gap in knowledge around GLP-1 side effects. To address the information gap and empower GLP-1 users with ongoing support during their health journeys, Advanced Herbals® is partnering with reality TV star Dolores Catania, to debut a new content series: "The Dish on GLP-1s." As a GLP-1 advocate who has spoken openly about her ups and downs with the medications, Catania is getting real about the one side effect that nearly derailed her progress and why she has used Advanced Herbals® Ginger Chews to help address her side effects – because nausea doesn't come with a heads up. "When I first started my wellness journey with GLP-1 medications, I was prepared for weight loss and I was ready to feel different, but the nausea? No one prepared me for that," said Dolores Catania. "It really impacted my day-to-day life, but at the time no one was having these open, honest conversations about GLP-1 use – there was still a lot of stigma and speculation." Real Talk + Real ExpertiseThe series, which debuted today on Instagram and YouTube, features candid conversations between Catania and Dr. Holly Lofton, a Board Certified Obesity Medicine Physician at NYU Langone. Dr. Lofton offers professional expertise, and Dolores Catania gets candid about her experiences as they unpack the real-life impact of GLP-1 side effects. Together, the two offer support and smart, stigma-free solutions, including how Advanced Herbals® Ginger Chews, with a clinically tested dose of ginger to help relieve nausea from morning sickness, motion sickness and upset stomach, may help individuals with nausea associated with their GLP-1 journey*. "GLP-1 medications work by slowing the rate at which the stomach empties, helping users feel full longer and ultimately consume fewer calories, but this mechanism can also lead to symptoms like nausea, bloating and constipation," said Dr. Holly Lofton. "These early symptoms and side effects can ultimately derail proper use of the drug or even deter potential new patients. That's why non-prescription, convenient options, like Advanced Herbals® Ginger Chews for nausea and Fleet® Stimulant Oral Laxatives for constipation, can be helpful tools in managing these common side effects." The series will air weekly across Dramamine's social platforms, offering relatable, expert-backed insights meant to inform, empower and resonate with the growing community of GLP-1 users looking for information on their wellness journeys. Follow @DramamineOfficial to learn more. "As some of the most common symptoms of GLP-1 medications, nausea and constipation have proven to be jarring and disruptive for GLP-1 users," said Erica Nesbitt, Associate Marketing Director at Prestige Consumer Health. "All indicators point to increased accessibility and continued use of GLP-1 medications, so we saw an opportunity with Fleet® Oral Laxatives, Liquid Glycerin Suppositories and Advanced Herbals® Ginger Chews to help support those on a journey to improve their health." Clinically Tested, Convenient ReliefAdvanced Herbals® Ginger Chews, from the makers of Dramamine®, are crafted with ginger extract that helps to provide non-drowsy relief from multiple cases of nausea including upset stomach, morning sickness, motion sickness and occasional heartburn. With a great tasting lemon-honey-ginger flavor and a clinically tested dose of ginger extract, these soft chews are convenient and safe for frequent use. Fleet® Stimulant Oral Laxatives are a gentle, oral option for constipation relief that are easy to bring on the go and Fleet® Liquid Glycerin Suppositories provide fast relief for occasional constipation, working within minutes. Advanced Herbals® Ginger Chews and Fleet® Oral Laxatives and Liquid Glycerin Suppositories can be purchased at retailers including Amazon, Target, Walmart, Walgreens and CVS. Survey Methodology: Advanced Herbals®, from the makers of Dramamine®, and Fleet conducted a consumer survey in collaboration with third-party research partner Opinium to obtain a nationally representative sample of ~ 1,000 U.S. adults who currently take GLP-1 medications. The survey was conducted in May 2025. About Dramamine®With over 75 years of experience, Dramamine® is the leader in nausea relief and the #1 pharmacist recommended brand in motion sickness. Dramamine®'s range of solutions, in various forms, effectively prevent and treat nausea, dizziness, vomiting & queasiness. The brand is part of Prestige Consumer Healthcare, a leading consumer healthcare products company which markets over-the-counter products in the U.S., Canada and Australia. For more information on Dramamine®, visit About Fleet® Fleet® is the #1 brand of enemas and suppositories, trusted for over 140 years to provide gentle, fast and effective relief from occasional constipation. Offering a range of over-the-counter solutions, Fleet® helps consumers manage digestive discomfort with confidence and convenience, no prescription required. For more information, visit About Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at *This statement has not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. View original content to download multimedia: SOURCE Dramamine
New York Times
08-07-2025
- Sport
- New York Times
Mike Brown on coaching the Knicks: ‘Nobody has bigger expectations than I do'
Mike Brown walked in confident and eager. His trademark thick glasses rested on the brim of his nose. A navy blue suit, orange pocket square and Knicks pin were part of his wardrobe. A smile as long as the ride from Madison Square Garden to Tarrytown, N.Y., where the Knicks practice, was plastered across his face. This was the look of a man in the moment, embracing each second. Advertisement A new journey was just beginning. Brown has had several of those throughout his 25-plus years in the NBA. He coached Kobe Bryant. He coached LeBron James. He's been to the NBA Finals. He was sitting in the passenger's seat in Golden State, along for the greatest ride the NBA has seen in some time. He made a disastrous franchise respectable, only to be fired less than three years in. Brown has been fired several times, twice after a single season. He's seen it all. Well, not yet. As Brown sits, he's the new head coach of the New York Knicks, a starved franchise with as much support as any in sports. Comparing this job to others he's held wouldn't be fair. Winning a title with the Knicks would be an achievement that can't be measured until it happens. New York was on the doorstep of its first NBA championship in more than 50 years and fired the man who helped build them up to that point. New York, a franchise with little to celebrate over the last two decades, decided that getting close under Tom Thibodeau wasn't good enough. Now, Brown becomes just the second head coach this decade to sit behind this exact microphone, and he becomes the first Knicks head coach in at least 20 years to face this kind of pressure. Welcome to New York. 'Nobody has bigger expectations, first of all, than I do,' Brown said. 'My expectations are high. This is the Knicks. I talked about Madison Square Garden being iconic. I talked about our fans. I love and embrace the expectations that come along with it. I'm looking forward to it.' Brown's name was circled at the start of the Knicks' coaching search. His experience as both a head coach and assistant intrigued New York's decision-makers. His work with some of the NBA's biggest stars was appealing. When the two sides finally sat down, Brown's willingness to collaborate with his assistants and the front office was a selling point that stuck with the people in charge, per league sources. Advertisement New York's winding search for a head coach lasted several weeks. It featured the organization reaching out to currently employed head coaches and being denied by all of their teams. It featured interviewing current assistant coaches, as well as holding conversations with college coaches, such as South Carolina's Dawn Staley. Ultimately, Brown was the only candidate to get a second interview for the head coaching vacancy, per league sources. The Knicks want to win a championship as soon as possible, and they have the talent to do that. Now, they believe they have the right coach, even if the process to get there included knocking on other doors along the way. 'I respect Leon's (Rose) process,' Brown said. 'I feel like I'm a detailed guy, thorough with everything I try to do. It's no different here. I was just myself throughout the process. I had great conversations with (James) Dolan and, obviously, Leon and his group. My whole thing is that I want to form a partnership with (Leon). I want to do this together. It's impossible to do it on your own. 'The outcome, obviously, is exciting for me because I'm sitting in the seat that I wanted to be in.' It's not every day that a newly hired head coach walks into a locker room with the talent level of the Knicks. Jalen Brunson is Batman and Karl-Anthony Towns is an overqualified Robin. OG Anunoby, Josh Hart and Mikal Bridges are as good a wing trio as you'll find without a single All-Star appearance. Miles McBride is a scorer and point-of-attack defender off the bench and Mitchell Robinson just wrapped up a postseason where he was as dominant as anyone on the roster. Over the last week, New York added more firepower to its second unit by bringing in Jordan Clarkson and Guerschon Yabusele. The Knicks can still add one more veteran-minimum player to the roster this offseason. Advertisement The foundation is there, and it's on Brown to best maximize the talent. New York finished the regular season with the fifth-best offense in the NBA, but that number was a bit deceiving. The Knicks had just the 16th-ranked offense from Jan. 1 to the end of the regular season (Brunson did miss a month in March due to injury). The Brunson-Towns pick-and-roll never truly terrorized defenses like it was supposed to. The offense as a whole struggled against premier defenses when healthy, even in the playoffs. This New York team was designed to be one of the best offenses in basketball. It never consistently hit that point last season. For the Knicks to secure an elusive championship, they'll need this offense to be humming. And that's where Brown comes back into play. While widely known for his defensive acumen, Brown coached one of the most efficient offenses in modern NBA history in his first season in Sacramento and has had a top-10 offense six times as a head coach. 'I thought what this group did this past year in the playoffs, it just shows their potential, not just defensively but offensively, too,' Brown said. 'I'm looking forward to putting a plan in place and working with those guys on both ends of the floor. I love their length and I love their versatility. So, implementing my vision is very exciting for me and, hopefully, it is for everyone else. I think the ceiling is high on both ends for the group.' There's a lot beyond talent that goes into winning an NBA championship. Just ask the Thunder and Pacers. Injuries, luck and timing all play into the equation. Brown might have been brought here to win a championship, but only so much is in one man's control. The Knicks made it clear that what the old head coach could dictate, despite being the most successful head coach the franchise has had in 20-plus years, didn't get the job done and wouldn't have going forward. New York's braintrust believes that either Brown's voice or the change in imagination — they're hoping for both — will raise the franchise to where those in charge believe it should be. Brown, who said he will collaborate with Rose throughout the offseason to finalize his coaching staff, enters a situation where the spotlight will be on him simply because of the expectations of his bosses. Whether that is fair or not, that's the reality. Brown will either be a hero in the greatest city in which to be one, or he'll just be another coach trying to find room in the revolving door. We're just a few months away from beginning to see which direction this thing will go. 'Our goal, starting with (James) Dolan, to Leon, to the players, all the way down to the fans is to build a sustainable, winning culture that produces championships,' Brown said. 'That's why I'm here.'
Fast Company
20-06-2025
- Business
- Fast Company
No more Mr. Nice Guy: The incomparable Michael Bierut steps down
On a Tuesday last fall, Michael Bierut was sitting in his living room in Tarrytown, New York, about 25 miles away from where he'd typically be on a weekday afternoon at any point over the previous few decades. Bierut, 67, had just stepped back from his role as partner at Pentagram, the storied graphic design studio that has shaped the branding for many of the world's most important companies, and he was feeling restless. 'It's been disconcerting for me,' Bierut said as we spoke with a view of the Hudson River sparkling from the window. He noted that the rest of Pentagram's partners were currently on an annual retreat in an undisclosed location. This was the first time he hadn't attended. 'I'm a really black-and-white person. I have two speeds. I do a lot, or I don't do it at all.' For most of his career, Bierut put on a suit and tie, took the Metro-North train from the suburbs to the city, and went to work. Now, he goes to the Flatiron office once a week in his new role as a strategist at-large, where he acts as a part-time consultant on retainer to his fellow partners. Bierut plans to use the rest of his time writing, teaching, and working on independent projects. He has a few ideas for design books.
Yahoo
20-06-2025
- Health
- Yahoo
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating, and relapsing rare skin disease affecting approximately 27,000 adults in the US whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the US to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly people Paris and Tarrytown, NY, June 20, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). BP primarily affects elderly patients, and is characterized by intense itch, painful blisters, and lesions, as well as reddening of the skin. It can be chronic and relapsing with underlying type 2 inflammation. The blisters and rash can form over much of the body and cause the skin to bleed and break down, resulting in patients being more prone to infection and affecting their daily functioning. Available treatment options are limited and can add to overall disease burden by suppressing a patient's immune system. Executive Director, International Pemphigus and Pemphigoid Foundation 'People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden. The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone.' Global Therapeutic Area Head, Immunology and Oncology Development, Sanofi 'Until now, treating bullous pemphigoid was very challenging for elderly patients struggling with the debilitating impact of blisters and lesions, and potentially co-morbid conditions. By addressing two central drivers of the underlying type 2 inflammation that contributes to bullous pemphigoid, Dupixent is the first targeted medicine to allow patients the potential to achieve sustained remission and reduce itch. This approval in the US is important for the thousands of patients living with bullous pemphigoid, and we look forward to working with regulators around the world to bring this innovative medicine to more patients in need.' The FDA approval is based on data from the pivotal ADEPT phase 2/3 study that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP. Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. During the FDA review, the analyses were updated; the FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are: 18.3% of patients experienced sustained disease remission compared to 6.1% (12.2% difference; 95% confidence interval: -0.8% to 26.1%), the primary endpoint 38.3% of patients achieved clinically meaningful itch reduction compared to 10.5% Median cumulative OCS dose was 2.8 grams compared to 4.1 grams In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis. Additionally, one case of acute generalized exanthematous pustulosis was reported in one patient treated with Dupixent and zero patients treated with placebo. Board co-Chair, President, and Chief Scientific Officer at Regeneron 'This approval extends the remarkable ability of Dupixent to transform treatment paradigms for people living with a variety of diseases with underlying type 2 inflammation, from common conditions like asthma and atopic dermatitis, to rarer ones such as eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid. Dupixent has shown the potential to improve the most challenging effects of bullous pemphigoid, while helping some patients achieve sustained disease remission and decreased oral corticosteroid use. Additionally, this approval further reinforces the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and across dermatological, respiratory, and gastrointestinal diseases.' The FDA evaluated Dupixent under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions. Dupixent was previously granted orphan drug designation by the FDA for BP, which applies to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the US. Additional regulatory applications are also under review around the world, including in the EU, Japan, and China. About the Dupixent BP pivotal studyADEPT was a randomized, phase 2/3, double-blind, placebo-controlled study evaluating the efficacy and safety of Dupixent in 106 adults with moderate-to-severe BP for a 52-week treatment period. After randomization, patients received Dupixent or placebo every two weeks after an initial loading dose, along with OCS treatment. During treatment, OCS taper was initiated after patients experienced two weeks of sustained control of disease activity. OCS tapering could start between four to six weeks after randomization and was continued if disease control was maintained, with the intent of completion by 16 weeks. After OCS tapering, patients were only treated with Dupixent or placebo for at least 20 weeks (rescue treatment could be used if required). The primary endpoint evaluated the proportion of patients achieving sustained disease remission at 36 weeks. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by 16 weeks without relapse after completion of the OCS taper and no rescue therapy use during the 36-week treatment period. Relapse was defined as appearance of ≥3 new lesions a month or ≥1 large lesion or urticarial plaque (>10 cm in diameter) that did not heal within a week. Rescue therapy could include treatment with high-potency topical corticosteroids, OCS (including increase of OCS dose during the taper or re-initiation of OCS after completion of the OCS taper), or systemic non-steroidal immunosuppressive medications, or immunomodulating biologics. Select secondary endpoints evaluated at 36 weeks included: Proportion of patients with ≥4-point reduction in Peak Pruritus Numerical Rating Scale (scale 0-10) Total cumulative OCS dose About DupixentDupixent (dupilumab) is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with BP, Dupixent 300 mg is administered every other week after an initial loading dose, and in combination with a tapering course of oral corticosteroids. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional. Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL4 and IL13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For more information, please call 1-844-DUPIXENT (1-844-387-4936) or visit Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic spontaneous urticaria, chronic obstructive pulmonary disease, and BP in different age populations. More than one million patients are being treated with Dupixent globally. Dupilumab development programDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit or follow Regeneron on LinkedIn, Instagram, Facebook or X. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Sanofi Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Le Bourhis | +33 6 75 06 43 81 | Rouault | +33 6 70 93 71 40 | Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Sanofi Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Châtelet | +33 6 80 80 89 90 | Li | +33 6 84 00 90 72 | Regeneron Media RelationsAnna Hodge | +1 914-255-6475| Regeneron Investor RelationsMark Hudson | +1 914-847-3482 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent® (dupilumab) for the treatment of bullous pemphigoid as discussed in this press release; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024, and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( and its LinkedIn page ( Press_ReleaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
19-06-2025
- Health
- Globe and Mail
Wellness Road Psychology Expands to Westchester County with New Tarrytown Location
"We've seen a growing need for high-quality mental health care outside Manhattan. Our new Tarrytown office allows us to bring our expert, evidence-based services to more individuals and families seeking support." Wellness Road Psychology, a leading NYC mental health clinic, opens a new office in Tarrytown, NY, expanding access to its evidence-based, drug-free therapy. With 25+ licensed therapists specializing in anxiety, depression, PTSD, child psychology, LGBTQ+ care, and couples counseling, the clinic has helped 3,000+ clients and earned 180+ five-star reviews. Led by Dr. Philip Glickman, the Tarrytown location offers in-person and online therapy. Tarrytown, NY - June 19, 2025 - Wellness Road Psychology, one of New York's leading providers of mental health services, is proud to announce the opening of a brand-new office in Tarrytown, NY. This expansion will make their evidence-based, drug-free psychotherapy services more accessible to residents of Westchester County and the surrounding areas. Led by Dr. Philip Glickman, Executive Director, the Wellness Road Psychology team consists of 25+ licensed therapists experienced in treating anxiety, depression, grief, PTSD, child psychology, LGBTQ+ mental health, couples counseling, and family therapy. Their compassionate and personalized approach has helped over 3,000 clients and earned the clinic more than 180 five-star reviews from grateful patients across NYC. ' We've seen a growing need for high-quality mental health care outside Manhattan,' said Dr. Glickman. ' Our new Tarrytown office allows us to bring our expert, evidence-based services to more individuals and families seeking support.' The Tarrytown location offers the same drug-free, non-prescription treatments that Wellness Road Psychology is known for — helping clients improve their mental health through proven psychotherapeutic methods. In addition to in-person sessions, the practice will continue offering online therapy options for maximum convenience. For more information or to schedule an appointment at the new Tarrytown office, visit or call (646) 798-2722.
